Polyrizon (PLRZ) Intangibles (2024 - 2025)
Polyrizon's (PLRZ) quarterly Intangibles came in at $2.5 million in Q4 2025, down 11.69% YoY from $2.9 million in Q4 2024, and down 5.56% on a QoQ basis from $2.7 million in Q2 2025.
Polyrizon (PLRZ) Intangibles (2024 - 2025) Analysis & Trends
Polyrizon (PLRZ) has 2 years of Intangibles data on file, last reported at $2.5 million in Q4 2025.
- Quarterly Intangibles fell 11.69% year-over-year to $2.5 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $2.5 million (down 11.69% YoY) and the FY2025 annual result came in at $2.5 million, down 11.69% from the prior year.
- Intangibles retreated to $2.5 million in Q4 2025, from $2.7 million in the prior quarter.
- In the past five years, Intangibles ranged from a high of $2.9 million in Q4 2024 to a low of $2.5 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 412.80 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.31 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 266.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 60.96 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 93.49 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Polyrizon | 7.27 Mn | -4.22 Mn | - | 2.55 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 2.55 Mn |
| Jun 30, 2025 | 2.70 Mn |
| Dec 31, 2024 | 2.88 Mn |